On June 26, Gelunhui reported that Hubei Jumpcan Pharmaceutical (600566.SH) announced that its wholly-owned subsidiary, Jumpcan Pharmaceutical Group Co., Ltd. (referred to as 'Jumpcan Limited') received the Drug Registration Certificate for Levofloxacin Sodium Chloride Injection issued and approved by the National Medical Products Administration. Levofloxacin is the levorotatory form of ofloxacin, with its antibacterial activity about twice that of ofloxacin. Its main mechanism of action is to inhibit the activity of bacterial DNA gyrase and inhibit bacterial DNA replication.
济川药业(600566.SH)：左氧氟沙星氯化钠注射液获得药品注册证书
Hubei Jumpcan Pharmaceutical (600566.SH): Levofloxacin Sodium Chloride Injection Obtains Pharmaceutical Registration Certificate.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.